[HTML][HTML] Immunotherapy in melanoma: recent advances and future directions
A Knight, L Karapetyan, JM Kirkwood - Cancers, 2023 - mdpi.com
Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …
recurrence for melanoma following surgical resection and improve survival in patients with …
Toll-like receptor 9 agonists in cancer
L Karapetyan, JJ Luke, D Davar - OncoTargets and therapy, 2020 - Taylor & Francis
Abstract Toll-like receptor 9 (TLR9) is a pattern recognition receptor that is predominantly
located intracellularly in immune cells, including dendritic cells, macrophages, natural killer …
located intracellularly in immune cells, including dendritic cells, macrophages, natural killer …
Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides
Designed oligonucleotides can self-assemble into DNA nanostructures with well-defined
structures and uniform sizes, which provide unprecedented opportunities for biosensing …
structures and uniform sizes, which provide unprecedented opportunities for biosensing …
The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity
DNA containing unmethylated CpG dinucleotides, or CpG motifs,(CpG DNA) has been
explored as a therapeutic agent, owing to its potent immunostimulatory activity. A previous …
explored as a therapeutic agent, owing to its potent immunostimulatory activity. A previous …
[HTML][HTML] MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside
B Wittig, M Schmidt, W Scheithauer… - Critical reviews in oncology …, 2015 - Elsevier
The adaptive immune system has been the main focus of immunological strategies in
oncology with only more recent approaches targeting innate immunity. Endosomal toll-like …
oncology with only more recent approaches targeting innate immunity. Endosomal toll-like …
Chimeric immunomodulatory compounds and methods of using the same—III
KL Fearon, D Dina, SF Tuck - US Patent 7,785,610, 2010 - Google Patents
WEIKWRHPSBSLNX-UHFFFAOYSA-N [5-(2-amino-6-oxo-3H-purin-9-yl)-3-hydroxyoxolan-2-
yl] methyl [5-(4-amino-2-oxopyrimidin-1-yl)-2-(phosphonooxymethyl) oxolan-3-yl] hydrogen …
yl] methyl [5-(4-amino-2-oxopyrimidin-1-yl)-2-(phosphonooxymethyl) oxolan-3-yl] hydrogen …
Enhanced immunostimulatory activity of oligodeoxynucleotides by Y‐shape formation
M Nishikawa, M Matono, S Rattanakiat… - …, 2008 - Wiley Online Library
DNA containing unmethylated CpG dinucleotides (CpG DNA) is a potent activator of innate
and acquired immune responses. Although the sequence‐specific immunostimulatory …
and acquired immune responses. Although the sequence‐specific immunostimulatory …
Emerging nanoparticle platforms for CpG oligonucleotide delivery
Unmethylated cytosine–phosphate–guanine (CpG) oligodeoxynucleotides (ODNs), which
were therapeutic DNA with high immunostimulatory activity, have been applied in …
were therapeutic DNA with high immunostimulatory activity, have been applied in …
Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides
M Martin-Armas, J Simon-Santamaria, I Pettersen… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: Bacterial DNA and synthetic oligonucleotides containing
unmethylated motifs have become the focus of many studies due to their ability to activate …
unmethylated motifs have become the focus of many studies due to their ability to activate …
Immunostimulatory properties of lipid modified CpG oligonucleotides
Innate immune responses recognizing pathogen associated molecular patterns play
important roles in adaptive immunity. As such, ligands which mimic the conserved products …
important roles in adaptive immunity. As such, ligands which mimic the conserved products …